Abstract
Neoadjuvant chemotherapy (NAC) has become an important treatment approach for stage II/III breast cancers to downsize tumor and enable breast-conserving surgery for patients that may otherwise undergo mastectomy. MR imaging has the potential to identify early response or disease progression, enabling potential modification to NAC regimens. Detection of size and morphologic changes is better appreciated with MR imaging than other modalities and is different between molecular subtypes of breast cancer. The combination of DCE-MR imaging and DWI provides the highest sensitivity and specificity. Other new modalities such as FDG PET/MR imaging and molecular breast imaging are still undergoing research.
Original language | English (US) |
---|---|
Pages (from-to) | 207-220 |
Number of pages | 14 |
Journal | Magnetic resonance imaging clinics of North America |
Volume | 26 |
Issue number | 2 |
DOIs | |
State | Published - May 2018 |
Keywords
- Breast cancer
- Inflammatory breast cancer
- Neoadjuvant chemotherapy
- Preoperative chemotherapy
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging